Statement of Changes in Beneficial Ownership (4)
February 13 2020 - 3:22PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Blunt Roshawn A. |
2. Issuer Name and Ticker or Trading Symbol
Adamis Pharmaceuticals Corp
[
ADMP
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
11682 EL CAMINO REAL STE 300 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
8/26/2019 |
(Street)
SAN DIEGO, CA 92130
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Appreciation Right | $.97 (1) | 8/26/2019 | | A | | 50000 | | (2) | 8/26/2026 | Common Stock | 50000 | $0 | 50000 | D | |
Explanation of Responses: |
(1) | Each Stock Appreciation Right is the economic equivalent of one share of ADMP common stock and can only be settled in cash. |
(2) | The Stock Appreciation Right ("SAR") will vest with respect to 8,333 shares subject to the SAR on the six-month anniversary of the date of grant, and thereafter 1,388 shares shall vest on each monthly anniversary of the date of grant with all remaining unvested shares subject to the SAR vesting on the thirty-sixth (36th) monthly anniversary of the date of grant. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Blunt Roshawn A. 11682 EL CAMINO REAL STE 300 SAN DIEGO, CA 92130 | X |
|
|
|
Signatures
|
/s/ Robert O. Hopkins, Power of Attorney for Roshawn A. Blunt | | 2/13/2020 |
**Signature of Reporting Person | Date |
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Apr 2024 to May 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From May 2023 to May 2024